Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-2.43% $4.82
America/New_York / 23 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 151.84 mill |
EPS: | -0.830 |
P/E: | -5.81 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 31.50 mill |
Avg Daily Volume: | 0.290 mill |
RATING 2024-04-23 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | |||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -5.81 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.99x |
Company: PE -5.81 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 4.34 - 5.30 ( +/- 9.92%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Kelliher Mike | Buy | 30 000 | Stock Option (Right to Buy) |
2024-01-02 | Kelliher Mike | Buy | 29 250 | Stock Option (Right to Buy) |
2024-01-02 | Kelliher Mike | Buy | 4 730 | Stock Option (Right to Buy) |
2024-01-02 | Kelliher Mike | Buy | 890 | Stock Option (Right to Buy) |
2024-01-02 | Gotwals Philip J | Buy | 29 250 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
82.28 |
Last 97 transactions |
Buy: 2 793 824 | Sell: 402 761 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.82 (-2.43% ) |
Volume | 0.478 mill |
Avg. Vol. | 0.290 mill |
% of Avg. Vol | 164.71 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.